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Abstract
The deposition of b-amyloid (Ab) into senile plaques and the impairment of somatostatin-mediated neurotransmission are
key pathological events in the onset of Alzheimer’s disease (AD). Insulin-degrading-enzyme (IDE) is one of the main
extracellular protease targeting Ab, and thus it represents an interesting pharmacological target for AD therapy. We show
that the active form of somatostatin-14 regulates IDE activity by affecting its expression and secretion in microglia cells. A
similar effect can also be observed when adding octreotide. Following a previous observation where somatostatin directly
interacts with IDE, here we demonstrate that somatostatin regulates Ab catabolism by modulating IDE proteolytic activity in
IDE gene-silencing experiments. As a whole, these data indicate the relevant role played by somatostatin and, potentially,
by analogue octreotide, in preventing Ab accumulation by partially restoring IDE activity.
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Introduction
The development of an efficient therapeutic strategy for the
treatment of Alzheimer’s disease (AD) requires a deeper
understanding of the biochemical mechanism which leads to
neuronal dysfunction and death [1]. Although molecular basis of
AD remains largely unclear, there is considerable evidence which
supports the so-called ‘‘amyloid cascade hypothesis’’: AD may be
viewed as a metabolic vicious cycle in which b-amyloid (Ab)
deposition into senile plaques drives neurodegeneration by
triggering abnormal microglia activation, tau protein hyperpho-
sphorylation and the consequent death of astrocytes and neurons.
Ab accumulation in the brain is the result of the imbalance
between its biosynthesis and removal [2,3]. Several proteases, such
as insulin-degrading-enzyme (IDE), neprilysin (NEP) and matrix
metalloproteinase 9 (MMP-9) are involved in Ab degradation [4–
6]. In this regard, a decrease in Ab-degrading enzymes expression
or activity, as a result of genetic factors, age and environmental
conditions, may be a crucial aspect in AD pathogenesis [7].
Notably, IDE is a zinc metalloendopeptidase that hydrolyzes a
wide range of substrates, including insulin, amylin, glucagon, atrial
natriuretic factor and insulin-like growth factors I and II [8]. Even
though its role in the onset of AD is not yet to be completely
understood [5], the relevance of IDE in AD pathogenesis has been
validated in works which have mapped the IDE gene on
chromosome 10 [9,10], making it a candidate gene for the AD-6
locus. Furthermore, it has been shown that, during aging, IDE
decreases in the brain of AD patients [11–13]. Additionally,
several studies underline a link between IDE haplotypes and SNPs
in the IDE gene, associating them to AD [14–16]. We have
recently demonstrated that somatostatin (sst) is a substrate and an
allosteric modulator of IDE activity, which enhances the
proteolytic processing of a synthetic Ab-peptide [17]. Somatostatin
depletion in the cortex and hippocampus of AD patients is directly
connected to memory and learning impairment [18–20] and a
strong reduction of sst-expressing neurons in the mouse CA1
hippocampal region seems to be associated to the onset of AD
[21]. Somatostatin seems to be also involved in the regulation of
neprilysin activity by affecting its expression and its synaptic
localization [22]. Although molecular mechanisms coupling
somatostatin depletion and AD remain unclear, somatostatin
transmitter replacement has been identified as a potential
pharmacological strategy for AD prevention [23,24]. Further-
more, the activation of somatostatin neurotransmission by sst-
releasing agents, such as FK960 and FK962, has been shown to
significantly improve cognitive performances in animal models
[25,26]. On the other hand, although in the past, the use of the
somatostatin analogue octreotide in clinical trials has not been
unequivocally associated to the restoration of cognitive functions,
there is some evidence which seems to demonstrate its potential
therapeutic value [24,27]. Since microglia secretes Ab and IDE
[28,29] and displays three functionally active receptor subtypes for
somatostatin (sst) (i.e. Receptors type 2, 3 and 4) [30,31], we
investigated sst effect on IDE expression in microglia cells. In this
work, we show that in activated microglia, somatostatin regulates
IDE expression, secretion and proteolytic activity toward Ab,
PLoS ONE | www.plosone.org 1 April 2012 | Volume 7 | Issue 4 | e34376which suggests that somatostatin pathological depletion could be
one of the key events leading to Ab deposition.
Materials and Methods
Materials
Mouse BV-2 microglial cells were kindly provided by Prof. D.
Rosato (University of Perugia, Italy) and N9 cells by Prof. R.
Ciccarelli (University of Chieti, Italy) [32,33]. Octreotide was a
generous gift from Italfarmaco. RPMI 1640, fetal bovine serum,
L-glutammine, penicillin, streptomycin, sodium pyruvate and
ciprofloxacin were purchased from Euro Clone (Life Sciences
Division, Italy). Minimum essential Eagle’s medium, fetal calf
serum, trypsin 2.5%, DNAse 1%, glucose, streptomycin, penicillin,
L-glutammine, L-leucine methyl ester were obtained from Sigma-
Aldrich (St. Louis, MO, USA). Human somatostatin was obtained
from Sigma-Aldrich (St. Louis, MO, USA); recombinant insulin
degrading-enzyme was purchased from Calbiochem (San Diego,
CA, USA); b-amyloid (1–40) was obtained from Anaspec (San
Jose, CA, USA). An IDE siRNA SmartPool and a non-specific
control pool were synthesized by Dharmacon (Lafayette, CO,
USA). Each pool contains four individual siRNA duplex
sequences. Lipofectamine and OptiMEM medium were obtained
from Invitrogen (Carlsbad, CA, USA). A b-amyloid(1–40) Elisa kit
was obtained from IBL-Humburg (Hamburg, Germany); an
RNasy Plus micro kit for RNA isolation was obtained from
Qiagen (Hilden, Germany) and a Masterscript kit and SYBER
ROX Master Mix came from 5PRIME (Humburg, Germany). All
other chemicals were from Sigma-Aldrich.
Methods
Cell culture. BV-2, a murine microglial cell line, was cultured
in RPMI 1640 supplemented with 15% fetal bovine serum (FBS),
L-glutammine (2 mM), penicillin (50 IU/ml), streptomycin
(50 mg/ml), sodium pyruvate (1 mM) and ciprofloxacin
(0.03 mM). Cells were seeded on 96-well plates (1610
4/well)
and grown overnight at 37uCi n5 %C O 2 [32].
Astrocytes and microglia cell cultures. Primary cultures
of glial cells were prepared from 2-day-old newborn rats (Sprague–
Dawley, Charles River, Calco, Italy). Cerebral hemispheres were
freed of the meninges and were mechanically disrupted. Cells were
dissociated in a solution of trypsin 2.5% and DNAse 1%, filtered
through a 100-mm nylon mesh, and plated in a 75 cm
2 flask
(5610
6/flask) in minimum essential Eagle’s medium (MEM)
supplemented with 10% fetal calf serum, glucose (0.6%),
streptomycin (0.1 mg/ml), penicillin (100 IU/ml) and L-glutam-
mine (2 mM). Glial cultures were fed twice a week and grown at
37uC in a humidified incubator with 5% CO2. A layer of astrocytic
cells was obtained through the vigorous shaking of a confluent 10-
day-old monolayer of mixed glial cells [34]. Cultures of enriched
astroglia were treated further with 5 mM L-leucine methyl ester to
eliminate microglia (97% homogeneity). Isolated astroglial prep-
arations were then seeded in 96-well plates (6610
4/well) in MEM
with supplements as above. Microglia were isolated by shaking
glial cultures at 260 rpm for 2 hrs. Microglia which dislodged into
the medium were purified by plating for 30 min in 96-well plates
(6610
4/well). Contaminating cells were removed with superna-
tant. These conditions allowed us to obtain highly enriched
microglial cultures with 98% homogeneity, as assessed by
immunocytochemistry with Griffonia simplicifolia isolectin B4.
All animal protocols have been performed to Department of
Pharmacological Sciences, University of Milan. The experiments
were designed so as to minimize the number of animals used.
Animal protocols for these studies have been approved for
Department of Pharmacological Sciences by the Ministry of
Health and were conducted with minimal suffering of the animals
and strictly following European Community (ECC Directive
no. 609/86) and local (Italian legislative Decree no. 116, January
27, 1992) regulations for animal care. All animal care procedures
were in accordance with the local Animal Care Committee, and
no weight loss or death was observed after we had received them
in our animal facility.
Treatment and sample preparation. Indicated concen-
trations of somatostatin (dissolved in 0.1 M phosphate buffer
pH 7.3) were added to the cell culture medium on the day after
plating. Stimulation was carried out overnight at 37uCi n5 %
CO2. Supernatants of stimulated and nonstimulated cells were
collected and frozen at 220uC until use, while the monolayers
were lysed in a solubilization buffer containing 50 mM NaCl, 1%
Triton, 50 mM Tris-HCl, 1 mM phenylmethylsulfonylfluoride in
the presence of a protease inhibitor cocktail with broad specificity
for the inhibtion of serine, cysteine, aspartic and aminopeptidases
(from Sigma-Aldrich).
Qualitative Insulin-degrading-enzyme analysis by
Western Blotting. Total protein concentration of cell lysates
was determined by a Bradford assay [35]. 10 mg of each sample
were separated on a 10% SDS-PAGE gel and transferred on
Hybond-ECL nitrocellulose filters (Amersham Biosciences, Piscat-
away, NJ, USA) for 1 h at 4uC. Membranes were blocked in a PBS
Tween (T-PBS) 0.01%, 5% fat-free milk solution, then probed
with IDE rabbit polyclonal antibody BC2 (Covance, Princeton,
NJ, USA, 1:3000 in T-PBS-0.1% and incubated with an Horse
Radish Peroxidase-conjugated anti-rabbit IgG antibody (Biorad,
Hercules, CA, USA, 1:50000 in T-PBS 0.2% fatty free milk).
Immunoreactive signals were detected with an ECL Advance
Western Blotting Detection Kit (Amersham Biosciences). Densi-
tometric analysis was performed by Image Quant TL program.
Secreted IDE quantification in BV-2 cell supernatants
by ELISA. IDE goat polyclonal antibody K-20 (Santa Cruz
Biotechnology, Santa Cruz, CA, USA) was diluted in PBS 16and
coated on a microtiter plate at a final concentration of 0.5 mg/ml.
Unsaturated binding sites were blocked in T-PBS-0.01% 5% fat-
free milk solution before exposure to BV-2 cell supernatants. An
IDE rabbit polyclonal antibody BC2 (1:3000in T-PBS 0.01%) and
a Horse Radish Peroxidase-conjugated anti-rabbit IgG antibody
(1:50000 in T-PBS 0.2% fat-free milk) were used for IDE
quantification. IDE concentration was determined by using a
TMB colorimetric kit according to product instructions. The
absorbance was measured at 450 nm in a microtiter plate reader
(Tecan, Switzerland). A standard curve was performed by using
known concentrations of recombinant IDE (Calbiochem).
Quantitative real-time PCR. The total RNA from each
sample of BV-2 cells was isolated using an RNeasy Plus micro kit
for RNA isolation according to the manufacturer’s instructions.
cDNA of total RNA was generated in two reaction volumes of
Masterscript kit using random hexamers. Real-time PCR was
performed by SDS7700 (Applied Biosystem, Foster City, CA,
USA) with Manual SYBER ROX Master Mix. GAPDH was
measured as the internal control. Primer sequences were:
ACGAGGCTATACGTCCAAGATTG and ATTGCCACCCG-
CACATTTT (Forward and Reverse, respectively) for IDE;
AACTTTGGCATTGTGGAAGG and CACATTGGGGG-
TAGGAACAC (Forward and Reverse, respectively) for GAPDH.
The following cycles were performed: initial denaturation cycle at
95uC for 2 min, followed by 40 amplification cycles at 95uC for
15 s, at 58uC for 30 s and at 68uC for 30 s.
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Blotting. Aliquots of supernatants from cell culture samples
were run under non-reducing denaturant conditions on 10%
polyacrylamide gels containing 1 mg/mL gelatine (Merck,
Darmstadt, Germany), soaked twice in 2.5% Triton X-100 for
20 min and then incubated for 18 hrs in the developing buffer
(20 mM Tris, 5 mM CaCl2, pH 7.4). For visualization purposes,
the gels were stained with Coomassie Brilliant Blue R-250 and
destained with 10% acetic acid and 20% methanol solution. For
the Western blotting analysis of MMP-9 in cell lysates, 10 mgo f
whole cell lysate were separated on 10% polyacrylamide gel and
then transferred onto a Hybond nitrocellulose membrane. Non-
specific sites were blocked with a 0.025% T-PBS 5% fat-free milk
solution and filters were then probed with a polyclonal anti-
MMP-9 antibody (Sigma Aldrich, St. Louis, CO 1:2000 in 0.1%
T-PBS) and thereafter with a Horse Radish Peroxidase-
conjugated anti-rabbit IgG antibody, (1:50000 in T-PBS 0.2%
fat-free milk). Immunoreactive signals were detected with an ECL
Advance Western Blotting Detection Kit (Amersham Bioscienc-
es).
IDE siRNA Transfection. BV-2 cells were used for
transfection when 30%–40% confluent in order to obtain the
greatest transfection efficiency. Cells were transfected with
20 pmol of IDE-siRNA or siRNA control pool using Lipofecta-
mine in OptiMEM media according to the manufacturer’s
recommendations. Somatostatin stimulation was performed 48 h
after transfection.
ß-amyloid(1–40) quantification in BV-2 conditioned
medium with sandwich ELISA. Human somatostatin was
added at different concentrations to the culture medium of control
and IDE-siRNA transfected BV-2 cells. According to the
manufacturer’s instructions, the incubation was carried out for
1 h at 37uC and the supernatants collected for b-amyloid(1–40)
quantification by ELISA. Equal volumes of each sample were
incubated overnight at 4uC on plates pre-coated with anti-Ab (35–
40) Mouse IgG. HRP conjugated anti-mouse Ab(1–16) rabbit IgG
was incubated at 4uC for 1 h. Reactivity was developed with TMB
for 30 min at room temperature and stopped with 1 N H2SO4.
The absorbance was measured at 450 nm with a microtiter plate
reader. A standard curve was obtained with Ab(1–40).
Statistical analysis. One-way analysis of variance (ANOVA)
was used to determine significant differences among groups.
Tukey’s honestly significant difference post hoc test was used for
pair wise comparisons after the analysis of variance.
Figure 1. Somatostatin induces an increase of IDE expression in microglia cells. Western blot analysis of normalized lysis samples from rat
primary microglia (A) and BV-2 (B) indicates that IDE level increases after 24 hrs of somatostatin incubation, while the internal control ß-tubulin is
constant. The additional incubation with sst after 6 hrs from first round strengthens the effect on IDE expression (left panel). Densitometric analysis of
IDE WB signals, average 6 ES of 5 independent experiments in triplicate (right panel). *P,0.05, one-way ANOVA, followed by Tukey’s test, n=15.
doi:10.1371/journal.pone.0034376.g001
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Somatostatin modulation of IDE expression
BV-2 cells as well as primary rat microglia were stimulated with
different sst concentrations and the IDE level was analyzed by
Western blotting in cell lysates collected after 24 hrs of incubation.
As shown in Figure 1, sst increases IDE expression in primary (A)
and BV-2 cells (B). Since sst half life in the serum is short [36], the
same sst concentration was re-added 6 hrs after the first
administration. This addition further amplifies the positive
modulation of IDE expression (Figure 1). It is interesting to note
that WB analysis on cell lysates of sst-stimulated N9 microglia cell
line confirms the enhancing effect on IDE expression (data not
shown). In order to assess whether the effect of sst on IDE
expression is a microglia characteristic, rat astrocytes which
display three sst receptor subtypes as well (SSTR-1, SSTR-2, and
SSTR-4) [37] were incubated with the same somatostatin
concentrations (Figure S1). IDE level was analyzed by Western
blotting in cell lysates collected after 24 hrs of sst incubation and as
indicated in Figure S1, no detectable modulation of IDE
expression was observed.
Since there was no principle difference in the response to
somatostatin in microglia cell lines compared to primary rat
microglia, immortalized BV-2 cells were subsequently used. The
sst-mediated up-regulation of IDE in BV-2 cells was further
checked by quantifying the mRNA using a RealTime-PCR. A
time-course investigation reveals that IDE mRNA increases
linearly with the sst concentration within 5 hrs to incubation
and turns back after 24 hrs, suggesting a transcriptional effect
triggered by sst in BV2 cells (Figure 2A).
Somatostatin effect on IDE secretion
It is known that a small fraction of IDE (ranging from 3% to
10%) is secreted into the extracellular space, where it presumably
interacts with its substrates, such as insulin and b-amyloid [8,38].
In order to determine whether, besides inducing synthesis, sst also
stimulates IDE secretion, the enzyme concentration in cell
supernatants was quantified 24 hrs after sst administration. As
reported in Figure 2B, the neuropeptide induces the increase of
IDE secretion in a similar way to WB and RT-PCR (Figue 1B and
2A). This result indicates that somatostatin acts not only by
modulating IDE expression, but also by affecting IDE secretion
and increasing the amount of the enzyme in the extracellular
space.
Somatostatin effect on MMP-9 activity
In addition to their ability to phagocyte b-amyloid, microglia
can also clear Ab by degradation through the production of Ab-
degrading enzymes, such as IDE, neprilysin and MMP-9
[29,33,39]. Therefore, we assessed whether sst is involved in the
regulation of MMP-9 level. For this purpose, BV-2 cells were
stimulated with different sst concentrations and MMP-9 activity
was measured by zymographyc analysis (Figure 3A). No detectable
modulation of MMP-9 gelatinolytic activity was observed for each
experimental condition. Qualitative analysis of MMP-9 content
was further performed on total cell lysates. A polyclonal anti-
MMP-9 antibody recognizes a single band around 92 kDa,
corresponding to the pro-MMP-9, which is constant over the
different sst concentrations (Figure 3B). This result rules out any
involvement of sst in the modulation of MMP-9 expression,
secretion and activity.
Octreotide modulation of IDE expression
Recently, somatostatin transmitter replacement has been
viewed as a potential AD therapeutical strategy [24,40]. In this
regard, BV-2 cells were stimulated with octreotide, a long-acting
Figure 2. Somatostatin modulation on IDE level in BV-2 cells.
(A) IDE mRNA increases after 5 hrs of incubation with somatostatin
(white columns); 24 hrs after incubation, the level is similar to the
control (grey columns). Basal mRNA levels were measured by real time
PCR in individual preparations of BV2. Data were first normalized
against GAPDH and then expressed setting the value measured in
controls at 1. The results presented are the means 6 ES (B) Elisa analysis
of conditioned medium indicates that IDE level increases in BV-2 cells
after 24 hrs of incubation as a function of somatostatin concentration.
The results presented are the means 6 SEs of five independent
experiments in triplicate. P,0.05, one-way ANOVA, followed by Tukey’s
test, n=15.
doi:10.1371/journal.pone.0034376.g002
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trials, in order to verify the effect on the expression pattern of IDE
[41]. 0.1–10 mM octreotide induces a dose-dependent increase of
IDE expression (Figure 4A) in a similar way to what can be
observed in the presence of somatostatin (Figure 1). A similar result
can also be obtained for IDE secretion, by using an ELISA assay
on BV-2 cell supernatants collected 24 hrs after the administration
(Figure 4B). Therefore, these findings indicate that octreotide and
sst exert a very similar effect on IDE expression and secretion in
BV-2 cells (see Figures 1, 2 and 4).
Somatostatin regulation of Ab(1–40) degradation by
insulin-degrading-enzyme
We have previously shown that somatostatin is an IDE substrate
and an allosteric modulator of recombinant IDE enzymatic
activity toward a fluorogenic b-peptide [17]. Therefore, we aimed
to verify whether sst by allosteric modulation of endogenous IDE
could affect the clearance of the Ab peptide secreted by BV-2 cells.
To this purpose, IDE expression was silenced through a siRNA-
based approach. At the maximum rate of IDE silencing
(corresponding to about 60%–70%, see Figure 5A), different
somatostatin concentrations (ranging between 0.01 mM and
0.5 mM) were added to the culture medium of both silenced and
non-silenced cells. Ab(1–40) was quantified in cell supernatants
after 1 h of somatostatin stimulation, a time interval during which
there was no accumulation of newly synthesized IDE, a fact that
was demonstrated through Western Blotting analysis on cell lysates
(data not shown). Ab(1–40) concentration was slightly reduced at
sst 0.01 mM in both silenced and not-silenced cells. In spite of this,
Ab(1–40) concentration was not further altered in the medium of
silenced cells by increasing sst concentrations, while it was
progressively reduced in the medium of non-silenced cells
(Figure 5B), suggesting that the reduction of Ab observed at sst
0.01 in silenced cells could be due to the effect of sst on residual
IDE. Therefore, at physiological concentrations, sst modulates
IDE activity also by promoting Ab(1–40) degradation in the BV-2
cells supernatants.
Discussion
Although several pathological mechanisms of AD progression
have been described, ranging from protein aggregation to
oxidative stress, mitochondrial failure, metal dyshomeostasis and
microglia dysfunction, the important role of amyloid deposition is
now widely recognized [7]. In this regard, the extracellular Ab
degrading enzymes (such as IDE, MMP-9 and NEP) are now
Figure 3. Effect of somatostatin on MMP-9 expression. (A) Zymographyc analysis of cell culture supernatants harvested after 24 hrs of
incubation indicate that somatostain administration does not modulate gelatinolytic activity of MMP-9 in each of the experimental conditions. (B) In
Western blotting analysis of cell lysates a polyclonal anti-MMP-9 antibody recognizes a single band corresponding to the pro-MMP-9 (92 kDa) which
is not modulated over each experimental condition. Analysis of b-tubulin represents the internal control. The results presented are the means 6 ES of
three indipendent experiments in triplicate, n=9.
doi:10.1371/journal.pone.0034376.g003
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Notably, IDE is the main extracellular protease secreted by
microglia involved in Ab degradation, even though the molecular
basis of IDE regulation are poorly known [5]. Microglia seems to
cover a two-fold role in AD pathogenesis. Firstly, early microglia
activation exerts a neuroprotective effect by promoting Ab
clearance. Secondly, as the disease progresses, the microglia Ab-
clearing capability is compromised [38,41]. This downregulation is
followed by an increase of Ab released by neurons and by a
worsening of the disease [32]. We previously demonstrated that sst
is an allosteric modulator of IDE [17]. In this work, we further
study the effect of sst on IDE showing that the neuropeptide
somatostatin also specifically regulates IDE, the main extracellular
Ab protease, by affecting its expression and secretion in both
primary and BV-2 microglia cells. Somatostatin triggers IDE gene
transcription and protein which displays a different turnover rate:
IDE-mRNA reaches a maximum of transcription within 5 hrs
after stimulation, returning to the basal level within 24 hrs,
whereas the protein concentration increases in cell lysates and
supernatants at later times, being still clearly evident after 24 hrs.
Through this pathway, somatostatin enhances IDE secretion,
strengthening the pool of active enzymes which interact with b-
amyloid and other IDE extracellular substrates. This effect is
specific for IDE since sst does not affect either secretion and
activity of MMP-9, another enzyme which is active in Ab
degradation. It is known that IDE and somatostatin levels are
altered in AD progression [3,20]. It is thus conceivable that sst
depletion results in a decrease of IDE expression and secretion
contributing to the pathological deposition of b-amyloid in the
brain. In addition, since the Ab chronic accumulation triggers a
further reduction in sst level [18], all these events could represent a
vicious cycle which ultimately favors Ab plaque formations. As
matter of fact, somatostatinergic transmitter replacement is a
potentially viable strategy in the treatment of AD, even though the
pharmacological restoration of this deficit has not been unequiv-
ocally associated to a recovery of normal cognitive performances
[24,26,40]. In this framework, we tested the octreotide effect on
IDE expression, a somatostatin analogue currently used in the
treatment of acromegaly, pituitary adenomes and pancreatic
tumors [41,42]. Here, we show that, like somatostatin, octreotide
increases IDE expression and secretion, although the effects are
generally reduced compared to the endogenous modulator.
Somatostatin binds all five receptor subtypes with high affinity,
whereas octreotide is a selective agonist, binding to receptor
subtypes 2 and 5 with high affinity (but lower than somatostatin)
and with moderate affinity to subtype 3 [41]. Therefore, this
evidence might explain the discrepancy between sst and its
analogue concerning the positive modulation of IDE expression,
even though additional factors cannot be ruled out. Interestingly,
we also observed that in astrocytes, incubation with somatostatin
Figure 4. Somatostatin analogue octreotide increases IDE expression and secretion. (A) WB (left panel) and densitometric analysis of IDE
(right panel) after 24 hrs incubation with the indicated concentrations of octreotide. (B) ELISA analysis on BV-2 medium after octreotide incubation
reveals that the sst analogue induces IDE secretion. In every case, the results presented are the means 6 ES of four independent experiments in
triplicate. * P,0.05, oneway ANOVA, followed by Tukey’s test, n=12.
doi:10.1371/journal.pone.0034376.g004
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reinforcing the physiological relevance of somatostatin action on
IDE secretion in microglia cells. This discrepancy is probably due
to the different expression pattern of sst receptor on microglia (i.e.
SSTR-2, SSTR-3, and SSTR-4) and astrocytes (i.e. SSTR-1,
SSTR-2, and SSTR-4) [31,35]. In our previous work, we reported
that somatostatin is an allosteric modulator of IDE enzymatic
activity on a fluorogenic Ab-peptide [17]. Here, we show that
somatostatin addition to the culture medium of BV-2 cells rapidly
affects the amyloid b-peptide (1–40) extracellular concentration:
after 1 h of stimulation (a time interval over which there is no
accumulation of newly synthesized IDE), we observe a negative
correlation between Ab concentration and sst concentration. The
lack of similar evidence in supernatants from IDE-silenced cells
suggests that the decrease in Ab levels is fully attributable to the
modulation of IDE activity secreted before sst administration. As a
whole, the reported data indicate that somatostatin regulates IDE
expression, secretion and catalytic activity in microglia. These
results are intriguing, considering that a microglia pharmacolog-
ical manipulation is thought to play a neuroprotective role at least
in the early stages of AD, since these cells cluster around senile
plaques promoting Ab phagocytosis and degradation [3,40,43].
Therefore, a correlation can be envisaged between the regulation
of IDE activity and the microglial immunological function during
the development of AD, opening a new therapeutic scenario for
the control of AD in the early phases.
Supporting Information
Figure S1 Modulation of IDE expression by somatostat-
in. Rat Astrocytes were incubated with indicated concentrations
of somatostatin. Western blot analysis of normalized lysis samples
indicates that no detectable effect of IDE expression is observed
(left panel). Densitometric analysis of IDE WB signals (right panel).
The results presented are the means 6 ES of three independent
experiments in triplicate, n=9.
(TIF)
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